# Biodistribution of 89Zirconium-labelled GSK2398852 Using PET Imaging

> **NCT03417830** · PHASE1 · TERMINATED · sponsor: **GlaxoSmithKline** · enrollment: 2 (actual)

## Conditions studied

- Amyloidosis

## Interventions

- **DRUG:** GSK2315698 (CPHPC)
- **DRUG:** GSK2398852 (unlabeled anti-SAP mAb)
- **DRUG:** 89Zr-GSK2398852 (89Zr-labeled anti-SAP mAb)

## Key facts

- **NCT ID:** NCT03417830
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2018-04-06
- **Primary completion:** 2018-07-20
- **Final completion:** 2018-07-20
- **Target enrollment:** 2 (ACTUAL)
- **Why stopped:** Change in benefit/risk profile.
- **Last updated:** 2019-08-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03417830

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03417830, "Biodistribution of 89Zirconium-labelled GSK2398852 Using PET Imaging". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT03417830. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*